Work

Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy

Year: 2020

Type: article

Abstract: Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor–based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials. See related article by Tannir et al., p. 78

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-20-3506

Authors: Joyce K. Hwang, Neeraj Agarwal, James Brugarolas, Tian Zhang

Institutions: Duke University, University of Utah, Huntsman Cancer Institute, The University of Texas Southwestern Medical Center, Duke Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute